Medicine and Dentistry
Patient
100%
Mycosis
61%
T Cell
42%
Allogeneic Hematopoietic Stem Cell Transplantation
42%
Hematopoietic Stem Cell Transplantation
34%
Hematology
30%
CHOP
30%
Cytokine
30%
Diagnosis
30%
Chemotherapy
30%
Stem Cell Transplant
30%
Biological Marker
30%
Acute Graft Versus Host Disease
30%
Human T-Lymphotropic Virus 1
30%
Adult T-Cell Leukemia/Lymphoma
30%
Daclizumab
30%
Combination Therapy
30%
Enalapril Maleate
30%
Experience
30%
Overall Survival
21%
Inpatient
13%
Transplantation
11%
Disease
9%
Disease Free Survival
8%
Serum
7%
Hazard Ratio
7%
Morbidity
7%
Donor
7%
Prophylaxis
7%
Therapeutic Procedure
5%
Mortality
5%
Incidence
5%
Analysis
5%
Multivariate Analysis
5%
Lymphocytosis
5%
Hypercalcaemia
5%
Hepatosplenomegaly
5%
Lymphoma Cell
5%
Prognosis
5%
Basiliximab
5%
Event Free Survival
5%
Lactate Dehydrogenase
5%
Skin Defect
5%
Lymphadenopathy
5%
Lymphoma
5%
Long Term Survival
5%
Cancer
5%
Combination Chemotherapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Human T-Lymphotropic Virus 1
30%
Daclizumab
30%
Combination Therapy
30%
T Cell Leukemia
30%
Overall Survival
10%
Lactate Dehydrogenase
5%
Lymphoma
5%
Chemotherapy
5%
Basiliximab
5%
Event Free Survival
5%
Long Term Survival
5%
Lymphadenopathy
5%
Hepatosplenomegaly
5%
Disease Free Survival
5%
Murine
5%
Skin Defect
5%
Tolerability
5%
Lymphocytosis
5%
Hypercalcemia
5%
Prognosis
5%
Immunology and Microbiology
Hematopoietic Stem Cell Transplantation
30%
Experience
30%
Allogeneic Hematopoietic Stem Cell Transplantation
30%
CCL2
11%
Overall Survival
10%
Incidence
5%
Survival
5%